Publicacions en què col·labora amb Paul Nguewa (17)

2015

  1. Leishmanicidal activities of novel methylseleno-imidocarbamates

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 9, pp. 5705-5713

  2. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells

    Prostate, Vol. 75, Núm. 11, pp. 1137-1149

  3. The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties

    Cancer Letters, Vol. 356, Núm. 2, pp. 899-909

2014

  1. Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications

    Clinical Genitourinary Cancer, Vol. 12, Núm. 2, pp. 87-93

  2. Id-1B, an alternatively spliced isoform of the inhibitor of differentiation-1, impairs cancer cell malignancy through inhibition of proliferation and angiogenesis

    Current Molecular Medicine, Vol. 14, Núm. 1, pp. 151-162

2013

  1. Spatial-temporal protein expression of inhibitor of differentiation-1 (Id1) during fetal embryogenesis and in different mouse and human cancer types

    Histology and Histopathology, Vol. 28, Núm. 8, pp. 1029-1040

2012

  1. Structure- and cell-specific effects of imidoselenocarbamates on selenoprotein expression and activity in liver cells in culture

    Metallomics, Vol. 4, Núm. 12, pp. 1297-1307

  2. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity

    Current Medicinal Chemistry, Vol. 19, Núm. 18, pp. 3031-3043

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

  2. Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology

    British Journal of Cancer, Vol. 105, Núm. 10, pp. 1608-1614

  3. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer

    Expert Opinion on Investigational Drugs, Vol. 20, Núm. 1, pp. 61-74

2010

  1. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

    BMC Cancer, Vol. 10

  2. Molecular characterization of the Gγ-globin-tagtransgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer

    Prostate, Vol. 70, Núm. 6, pp. 630-645

  3. Use of transgenic mice as models for prostate cancer chemoprevention

    Current Molecular Medicine, Vol. 10, Núm. 8, pp. 705-718

2009

  1. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

    British Journal of Cancer, Vol. 100, Núm. 6, pp. 932-940

2008

  1. Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens

    BMC Molecular Biology, Vol. 9

2007

  1. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1197-1204